Skip to main content

Part of Cancer staging guidance sheets

Lung (ICD10 C34)

Current Chapter

Current chapter – Lung (ICD10 C34)


Introduction

This is the data sheet for TNM 9th edition staging of the lung (ICD10 C34)

For more detailed information regarding TNM staging, please see pages 109-113 of the UICC TNM 9 book.


Stage groupings

Stage Group

T stage

N stage

M stage

Occult carcinoma

TX

N0

M0

Stage 0

Tis

N0

M0

Stage IA1

T1mi

N0

M0

 

T1a

N0

M0

Stage IA2

T1b

N0

M0

Stage IA3

T1c

N0

M0

Stage IB

T2a

N0

M0

Stage IIA

T1

N1

M0

 

T2b

N0

M0

Stage IIB

T1

N2a

M0

 

T2

N1

M0

 

T3

N0

M0

Stage IIIA

T1

N2b

M0

 

T2

N2a

M0

 

T3

N1, N2a

M0

 

T4

N0, N1

M0

Stage IIIB

T1

N3

M0

 

T2

N2b, N3

M0

 

T3

N2b

M0

 

T4

N2a, N2b

M0

Stage IIIC

T3, T4

N3

M0

Stage IVA

Any T

Any N

M1a, M1b

Stage IVB

Any T

Any N

M1c1, M1c2


TNM clinical classification

T - primary tumour

T value

Description

cTX

Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy

cT0

No evidence of primary tumour

cTis

Carcinoma in situa

cT1

Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, or tumour in a lobar or more peripheral bronchusb 

cT1mi - Minimally invasive adenocarcinomac

cT1a - Tumour 1 cm or less in greatest dimensionb

cT1b - Tumour more than 1 cm but not more than 2 cm in greatest dimensionb

cT1c - Tumour more than 2 cm but not more than 3 cm in greatest dimensionb

cT2a

Tumour more than 3 cm but not more than 4 cm in greatest dimension OR tumour not more than 4 cm in greatest dimension that invades one or more of the following

• The main bronchus (up to the carina, but without involvement of the carina)

• Invades visceral pleura

• An adjacent lobe

• Is associated with atelectasis or obstructive pneumonitis that extends to the hilar region either involving part of or the entire lung

• Invades an adjacent lobe

cT2b

Tumour more than 4cm but no more than 5cm in greatest dimension

cT3

Tumour more than 5 cm but not more than 7 cm in greatest dimension OR tumour not more than 7 cm that directly invades any of the following: Parietal pleura, chest wall (including superior sulcus tumours), pericardium, phrenic nerve, azygos veind , thoracic nerve roots (i.e., T1, T2), stellate ganglion or separate tumour nodule(s) in the same lobe as the primary

cT4

Tumour more than 7 cm OR tumour of any size that invades any of the following: mediastinum, thymus, trachea, carina, recurrent laryngeal nerve, vagus nerve, oesophagus, diaphragm, heart, aorta, superior or inferior vena cava, intrapericardial pulmonary arteries or veins, supra-aortic arteries, brachiocephalic veins, subclavian vessels, vertebral body, lamina, spinal canal, cervical nerve roots, brachial plexus or separate tumour nodule(s) in a different ipsilateral lobe to that of the primary

Notes:

General For non-mucinous lung adenocarcinomas, tumour size for the clinical T category is based on the size of the solid component seen on CT at lung windows (continuous thin section thickness, ≤1.5 mm) for part-solid nodules. At pathological assessment, if a nonmucinous adenocarcinoma has both lepidic and invasive components, the size of the invasive part is used for determining the pathological T category. For other tumour types, including invasive mucinous adenocarcinomas, the total tumour size is used both radiologically and pathologically in determination of the size descriptor of the T category.

Specific - 

a Tis includes adenocarcinoma in situ – Tis(AIS) – and squamous carcinoma in situ – Tis (SCIS). Adenocarcinoma in situ by CT imaging should show a pure ground glass nodule ≤3.0 cm for cTis (AIS). For pTis (AIS), the tumour should be of pure lepidic growth without any invasion with a total size ≤3.0 cm, thus having an invasive size of 0 cm.

bThe uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.

c Solitary adenocarcinoma (not more than 3 cm in greatest dimension), with a predominantly lepidic pattern and not more than 0.5 cm invasion in greatest dimension.

d Although these structures lie within the mediastinum invasion of these structure is not considered sufficient mediastinal penetration to be classified as a T4 category.

N - regional lymph nodes

N value

Description

cNX

Regional lymph nodes cannot be assessed

cN0

No regional lymph node metastasis

cN1

Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and/or intrapulmonary nodes, including involvement by direct extension

cN2

Metastasis in ipsilateral mediastinal and/or subcarinal lymph node station(s)

cN2a – Metastasis in a single station

cN2b – Metastasis in multiple ipsilateral stations

cN3

Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)

M - distant metastasis

M value

Description

cM0

No distant metastasis

M1

Distant metastasis

cM1a - Separate tumour nodule(s) in a contralateral lobe, tumour with pleural or pericardial nodules or malignant pleural or pericardial effusione

cM1b - Single extrathoracic metastasis in a single organ or organ systemf

cM1c - Multiple extrathoracic metastasis in a single or multiple organ(s) or organ system

cM1c1 - Multiple extrathoracic metastasis in a single organ or organ system

cM1c2 - Multiple extrathoracic metastasis in multiple organs or organ system(s)

Notes

eMost pleural (pericardial) effusions with lung cancer are due to the tumour. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is non‐bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging descriptor.

fThis includes the involvement of a single non-regional node.


TNM pathological classification

pT - primary tumour

The pT and pN categories correspond to the cT and cN categories as per above.

pN - regional lymph nodes

pN value

Description

pN0

Histological examination of hilar and mediastinal lymphadenectomy specimen(s) will ordinarily include 6 or more lymph node stations. Three of these stations should be mediastinal, including the subcarinal nodes and three from N1 stations. Labelling according to the IASLC chart and table of definitions given in the TNM Supplement is desirable. If all the lymph nodes examined are negative, but the number ordinarily examined is not met, classify as pN0.


Download

Click on the box below to download a PDF version of this staging sheet:

Last edited: 19 January 2026 12:13 pm

  1. Cancer staging guidance sheets
  2. Oral Cavity and mucosal lip (ICD10 C00.3-5, C02-C06)
  3. Malignant melanoma of upper aerodigestive tract (ICD10 C00-06, C09-14, C30-32)
  4. Pharynx (ICD10 C01, C02.4, C05.1-2, C09, C10.0, C10.2-3, C10.9, C11-13)
  5. Salivary glands (ICD10 C00-C14, C15.0, C30-C33, C41.1)
  6. Oesophagus including oesophagogastric junction (ICD10 C15, C16.0)
  7. Gastrointestinal stromal tumours (ICD10 C15-C20, C48.1-2)
  8. Stomach (ICD10 C16 - excluding C16.0)
  9. Small intestine (ICD10 C17)
  10. Appendix (ICD10 C18.1)
  11. Colon and rectum (ICD10 C18-C20)
  12. Anal and perianal skin (ICD10 C21)
  13. Liver (ICD10 C22.0)
  14. Intrahepatic bile ducts (ICD10 C22.1)
  15. Gallbladder (ICD10 C23)
  16. Distal extrahepatic bile duct (ICD10 C24.0)
  17. Perihilar bile ducts (ICD10 C24.0)
  18. Ampulla of vater (ICD10 C24.1)
  19. Pancreas (ICD10 C25)
  20. Nasal cavity and paranasal sinuses (ICD10 C30.0, C31.0, C31.1)
  21. Larynx (ICD10 C32.0, C32.1, C32.2, C10.1)
  22. Lung (ICD10 C34)
  23. Thymus tumours (ICD10 C37.9)
  24. Soft tissues (ICD10 C15-C26, C34-C37 C38.1-3, C47-C49, C51-C53, C58, C60-C68)
  25. Bone (ICD10 C40, C41)
  26. Melanoma of skin (ICD10 C00.0-2, C00.6, C21.2, C43, C51, C60, C63.2)
  27. Merkel cell carcinoma of skin (ICD10 C00, C44, C51, C60, 63.2, C80)
  28. Skin carcinoma of the head and neck (ICD10 C00.0-2, C00.6, C44.0, C44.2-4)
  29. Carcinoma of skin of the eyelid (ICD10 C44.1)
  30. Carcinoma of skin (excluding eyelid, head and neck, perianal, vulva and penis) (ICD10 C44.5-7, C63.2)
  31. Pleural mesothelioma (ICD10 C38.4)
  32. Breast tumours (ICD10 C50)
  33. Vulva (ICD10 C51)
  34. Cervix uteri (ICD10 C53)
  35. Uterine sarcomas
  36. Uterus - endometrium (ICD10 C54.1, C55)
  37. Ovarian, fallopian tube and primary peritoneal carcinoma (ICD10 C56, C57, C48.1, C48.2)
  38. Gestational trophoblastic neoplasms (ICD10 C58)
  39. Penis tumours (ICD10 C60)
  40. Prostate tumours (ICD10 C61.9)
  41. Testis tumours (ICD10 C62)
  42. Kidney tumours (ICD10 C64)
  43. Renal pelvis and ureter tumours (ICD10 C65 & C66)
  44. Urinary bladder tumours (ICD10 C67)
  45. Urethra tumours (ICD10 C68.0, C61.9)
  46. Carcinoma of conjuctiva (ICD10 C69.0)
  47. Melanoma of conjuctiva (ICD10 C69.0)
  48. Retinoblastoma (ICD10 C69.2)
  49. Melanoma of uvea (ICD10 C69.3-4)
  50. Carcinoma of lacrimal gland (ICD10 C69.5)
  51. Sarcoma of orbit (ICD10 C69.6)
  52. Thyroid gland (ICD10 C73.9)
  53. Adrenal cortex (ICD10 C74.0)
  54. Adrenal medulla and extra-adrenal paraganglia (ICD10 C74.1 C75.5)
  55. Parathyroid gland (ICD10 C75.0)
  56. Unknown primary - cervical nodes (ICD10 C77.0)
  57. Mycosis fungoides or sezary syndrome (ICD10 C84.0 and C84.1)
  58. T and B cutaneous lymphoma (ICD10, C82.6, C84.8, C86.6 and other C83-C86 if primary skin excluding C84.0 C84.1)
  59. Rhabdomyosarcoma (CTYA)
  60. Chronic lymphocytic leukaemia
  61. Hepatoblastoma (CTYA)
  62. Hodgkins and non-hodgkins lymphoma (ICD10 C81-88)
  63. Medulloblastoma
  64. Multiple myeloma
  65. Neuroblastoma
  66. Neuroendocrine tumours of the foregut
  67. Neuroendocrine tumours of the midgut and hindgut
  68. Non-hodgkin lymphoma (children)
  69. Wilms tumour of the kidney